Previous 10 | Next 10 |
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced presentations in the following scientific conferences during the month of October: 17th International C...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021. ...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will present at the Benzinga Healthcare Small Cap Conference on Thursday, September ...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following scientific conferences during the month of September: TIDES USA 2021 ...
The following slide deck was published by Exicure, Inc. in conjunction with this event. For further details see: Exicure (XCUR) Corporate Overview
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following investor conferences during the month of September: Citi’s 16th A...
Entered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders Presented Progress in Three Promising Neuroscience Programs including Friedreich’s Ataxia, Neuropathic Pain and Batten Disease at R&D Day Announced Interim Results for ...
Response rate threshold achieved to continue advancing patient enrollment in Phase 2 Merkel cell carcinoma (MCC) dose-expansion cohort Confirmed overall response rate (ORR) of 21% in all evaluable MCC patients enrolled in the Phase 1b/2 study Median duration of four ...
Exicure , Inc. ® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 ...
Gainers: Ever-Glory International Group (NASDAQ:EVK) +122%. Infinity Pharmaceuticals (NASDAQ:INFI) +33%. Exicure (NASDAQ:XCUR) +34%. Xenetic Biosciences (NASDAQ:XBIO) +31%. Atlas Technical Consultants (NASDAQ:ATCX) +28%. Annovis Bio (NYSE:ANVS) +22%. Full Truck Alliance (NYSE:YMM) +21%. Allie...
News, Short Squeeze, Breakout and More Instantly...
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely f...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...